JPRN-jRCT2080222155未知3 期
Phase III clinical study of DQ-2466 -Double-blind controlled study of fixed-dose and up-titration DQ-2466 regimens in subjects with persistent or permanent atrial fibrillation
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 120 人开始时间: 2013年7月26日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who are diagnosed as persistent or permanent atrial fibrillation and have excessive mean heart rate above 80 beats per minute on Holter ECG.
排除标准
- •.Patients who recently took a beta-blocker or a calcium antagonist (e.g., diltiazem or verapamil)
- •.Patients receiving treatment for heart failure (NYHA classes II to IV).
- •.Patients with contraindication of carvedilol therapy.
- •.Patients with poorly controlled diabetes mellitus or hypertension.
- •.Patients with hepatic or renal impairment.
研究者
相似试验
未知
3 期
A phase III study of KW-2246JPRN-jRCT2080221423Kyowa Hakko Kirin Co., Ltd.
未知
3 期
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)Parkinson's DiseaseJPRN-jRCT2080220980Kyowa Hakko Kirin Co., Ltd.20
已完成
3 期
A Comparative Study of KW-2246Cancer Related Pain (Breakthrough Pain)NCT01326689Kyowa Kirin Co., Ltd.42
未知
3 期
Phase 3 clinical study of DU-6859a in patients with respiratory tract infectioJPRN-jRCT2080220704DAIICHISANKYO Co.,Ltd.150
进行中（未招募）
1 期
A Phase 1/2 study of S-268019 (COVID-19)JPRN-jRCT2031210269agata Tsutae60